Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org, and the International HAE Association's website at: www.haei.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile infection.

ViroPharma routinely posts information, including press releases, which may be important to investors in the
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... -- The Association of periOperative Registered Nurses (AORN) has awarded ... Stop and Go Sign designed by Christopher ... M.D., anesthesia providers with Anaesthesia Associates of Massachusetts ... is distributed by the Plexus Management Group, Inc. ... compliance with the AORN Safe Surgery Checklist. ...
(Date:5/5/2015)... , May 5, 2015 Merrimack Pharmaceuticals, ... of a randomized, double-blinded, placebo-controlled Phase 2 clinical ... and ErbB3, in combination with nab-paclitaxel and gemcitabine, ... newly-diagnosed metastatic pancreatic cancer who have high serum ... is the fourth leading cause of cancer death ...
(Date:5/5/2015)... May 5, 2015   Cynosure, Inc. (Nasdaq: ... devices for aesthetic procedures and precision surgical applications worldwide, ... March 31, 2015. First-Quarter Highlights: , ... , Non-GAAP earnings of $0.15 per share; GAAP earnings ... at March 31, 2015 "Cynosure delivered 21 ...
Breaking Medicine Technology:The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 2The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 2Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 3Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 2Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 3Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 4Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 5Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 6Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 7Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 8Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 9Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 10Cynosure Announces First-Quarter 2015 Results; Posts Record First-Quarter Revenue of $74.9 Million, Up 21 Percent from Prior Year 11
... today-, SAN CARLOS, Calif., March 17 Nuvelo, ... the Phase 2 program in,catheter occlusion (CO), known as ... Alfimeprase), did not,show sufficient improvement in catheter opening at ... meet the desired target product,profile. As a result, Nuvelo ...
... Findings, BEDMINSTER, N.J., March 17 NPS,Pharmaceuticals, ... top-line,results from a 28-week blinded Phase 3-extension study ... who are dependent,upon parenteral nutrition (PN). The extension ... had completed a 24-week randomized Phase 3 study ...
Cached Medicine Technology:Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 2Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 3Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 4NPS Reports Successful GATTEX(TM) Extension Study 2NPS Reports Successful GATTEX(TM) Extension Study 3NPS Reports Successful GATTEX(TM) Extension Study 4NPS Reports Successful GATTEX(TM) Extension Study 5
(Date:5/5/2015)... (PRWEB) May 05, 2015 On April ... Los Angeles, CA, Choices Recovery sponsored Durkin Entertainment’s “RockNRolla” ... LA’s leading producer of sustainable product placement in TV ... the world’s top providers of ecologically sound and socially ... premier red carpet event that makes appearances at various ...
(Date:5/5/2015)... 2015 Don’t have time to go ... fitness membership? Don’t know which workout equipment to use? ... order to help members achieve their heath and fitness ... an educational, caused-based wellness company, today announces the launch ... classes led by certified trainers, nutritional information and recipes ...
(Date:5/5/2015)... Rafael, CA (PRWEB) May 05, 2015 ... in 2012, with the belief that ultimate Frisbee™ is ... be the next sport that engages the world. Nike ... youth level, by creating opportunities for young athletes to ... this collaboration with MLU the perfect fit. , The ...
(Date:5/5/2015)... Igantia , an emerging biotechnology and ... initiative to examine key biological milestones during a woman’s ... Scientists at Igantia believe that better understanding of the ... her menstrual cycle to her transition into menopause, they ... extend the lifespan. , By recently announcing the ...
(Date:5/5/2015)... After record-breaking sales of Extend Nutrition’s ... the Cookies & Cream flavor at stores nationwide this ... continually raised the bar for nutritional snacks. The ... unprecedented nutritional profile, backed by international patents and clinical ... launch additional new products and expand retail availability throughout ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 2Health News:Live Streaming Fitness Creates Industry Shift by Bringing Fitness, Nutrition and Cooking Classes to Smart Devices 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4
... ... Midlands area of South Carolina to reach their weight loss goals through her physician-supervised ... of impressive medical credentials. , ... Columbia, SC (PRWEB) June 10, 2009 -- Columbia Physician, Pamela Lyon, M.D. ...
... to a research abstract that will be presented on Wednesday, ... the Associated Professional Sleep Societies, symptoms of Rheumatoid Arthritis (RA) ... depression and poor adherence to RA medications. ... RA disease activity, level of pain, depression symptoms and adherence ...
... , NEW STATE-LEVEL DATA SHOW DISPARITIES VARY WIDELY ACROSS STATES ... U.S. Surgeon General David Satcher called for the elimination of ... continue to fare worse than white women on a variety ... determinants of health according to a new study by the ...
... New Guide to be Unveiled by SharpBrains CEO on June 11th, ... , SAN FRANCISCO, June 9 How can you take care ... articles and studies which seem to contradict each other? Do supplements ... or is one of them enough? Which brain training approach, if ...
... cell transplant (SCT) from a compatible donor early in the ... of young and middle-aged adult patients with acute myeloid leukemia ... studies. The findings of the study, published in the ... Medical Association by researchers at Dana-Farber Cancer Institute and ...
... young women outnumber young men, research shows the hemlines rise ... less pressure to settle down as more women compete for ... 30s, the reverse is true and proportionately more older men ... Daniel Kruger, a University of Michigan researcher who studies evolution ...
Cached Medicine News:Health News:Pamela Lyon, M.D. Achieves Board Certification in Bariatric, Weight Loss Medicine 2Health News:Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 2Health News:Sizable Health Disparities Evident in Every State Between Women of Different Racial and Ethnic Groups 3Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 2Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 3Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 4Health News:First Brain Training Consumer's Guide Debunks Ten Brain Health Myths and Reviews 21 Products 5Health News:Study IDs benefit of donor SCT for adults with acute myeloid leukemia 2Health News:When young men are scarce, they're more likely to play the field than to propose 2
... MIRAX SCAN is the system solution for digital ... monitor, a dual processor PC and software modules. ... scanner, which makes the specimens available as Digital ... quality, with the same optical resolution as on ...
... 1400 Series Biosafety Cabinets ... revolutionize working in a ... most comfortable, quiet, and ... cabinet on the market, ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
Velcro® Tracheostomy tube holders are available in Adult, pediatric, and infant sizes....
Medicine Products: